US Biosimilar Fee Collections Fall Short
The FDA Has Modified Its Carryover Spend-Down Plan
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.
You may also be interested in...
Up to $1m per year per award is available for projects that address significant issues with biosimilar or interchangeable product development.
The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.
Prescription drug user fee "receivables" nearly doubled in FY 2018, but the US FDA is not worried.